Axcella gets the ax: Flagship-founded biotech closes doors after 12-year run

Preview

来源: FierceBiotech

After a 12-year run, clinical-stage Axcella is closing.

Flagship-founded Axcella Health is closing its doors, with stockholders approving the dissolution of the metabolic modulator biotech yesterday.

Founded by Flagship Pioneering in 2011, the public biotech—previously known as Axcella Therapeutics—will be liquidating and dissolving, according to Dec. 4 documents filed with the SEC.

The vote follows the Nov. 1 termination of President and CEO William Hinshaw, Jr., as well as Chief Legal Officer Paul Fehlner, as the biotech prepared for the company’s closure.

The company has been struggling for at least the last year, restructuring in December 2022 with an 85% workforce reduction that included the company’s Chief Financial Officer Robert Crane and Chief People Officer Virginia Dean. The company also suspended a phase 2b clinical trial assessing AXA1125—an orally active mixture of amino acids—for nonalcoholic steatohepatitis, choosing to instead focus on treating long COVID.

Clearly, those efforts didn’t pan out. Axcella now joins an extensive list of companies that have entered the biotech graveyard this year, including another Flagship-founded business in Rubius Therapeutics. Flagship has declined Fierce Biotech's request for comment.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。